<DOC>
	<DOC>NCT02632786</DOC>
	<brief_summary>This is a global, multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who had a hematologic response to previous treatment for their amyloidosis (e.g., chemotherapy, autologous stem cell transplant [ASCT]) and have persistent cardiac dysfunction.</brief_summary>
	<brief_title>The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis</brief_title>
	<detailed_description />
	<mesh_term>Amyloidosis</mesh_term>
	<criteria>1. Age ≥18 years 2. Confirmed diagnosis of systemic AL amyloidosis 3. ≥1 prior systemic plasma cell dyscrasia therapy with at least a partial hematologic response 4. Cardiac involvement 5. NTproBNP ≥650 1. NonAL amyloidosis 2. Meets the International Myeloma Working Group (IMWG) definition of Multiple Myeloma 3. NTproBNP &gt;5000 4. Received Plasma cell directed chemotherapy within 6 months 5. Received autologous stem cell transplant (ASCT) within 12 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>amyloidosis</keyword>
	<keyword>ntprobnp</keyword>
	<keyword>NEOD001</keyword>
	<keyword>Prothena</keyword>
	<keyword>PRONTO</keyword>
	<keyword>amyloid</keyword>
	<keyword>plasma cell dyscrasia</keyword>
	<keyword>immunotherapy</keyword>
</DOC>